This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RXi Pharmaceuticals Appoints Robert Bitterman And Keith Brownlie To Board Of Directors

RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Robert Bitterman and Keith Brownlie have been appointed to the Company’s Board of Directors. Mr. Bitterman and Mr. Brownlie both bring extensive industry experience that will be instrumental to supporting RXi’s growth and development initiatives.

Mr. Bitterman brings over 18 years of leadership experience in the pharmaceutical and biologic life science industry to RXi. Mr. Bitterman currently serves as the President & CEO of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, LTD, a specialty pharma company focused on diseased and aging skin. Prior to Cutanea, he served as President and CEO for Isolagen, Inc., an international public, bioscience technology company whose primary proprietary platform used human fibroblasts for soft tissue enhancement. For 10 years, Mr. Bitterman served as the President and GM of Aventis' Dermik Laboratories, a global strategic business unit focused on therapeutic and aesthetic dermatology development and commercialization. “We are honored to have Robert join our Board of Directors,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that “His broad experience in the field of dermatology will be a valuable resource to RXi as we progress our first candidate into the clinic.”

Mr. Brownlie comes to RXi after a distinguished career with Ernst & Young that spanned 36 years. During his tenure, he rapidly became one of the leading accounting specialists for life sciences companies of the greater New York area. For the last 20 years at Ernst & Young, he has held the position of Metro New York Area Life Sciences Industry Leader. Mr. Brownlie has extensive experience with SEC registration statements, initial public offerings and recurrent reporting. In his accounting career he has been involved in over 100 public offerings. Until 2010, when he retired from Ernst & Young, he was a member of Ernst & Young’s National Life Sciences Committee, and he is a member of the American Institute of CPAs. Mr. Brownlie is currently a member of the Board of Directors of Epicept and Soligenix, where in both companies he also is chairman of the Audit Committee. “It is privilege for us at RXi to have someone of the caliber of Keith join RXi’s Board of Directors,” said Dr. Cauwenbergh. He added that “Keith joins us at a time that we expect to see RXi transform form a pure research platform company into a biotechnology product development company. His expertise will be beneficial in supporting and expediting this transition.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs